-
Pro Bono Bio announces the successful development of subcutaneous and long-acting blood factors VIIa, VIII and IX for the treatment of haemophilia
Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide London/Moscow 11 September 2012 – Pro Bono Bio Group plc (“PBB”), the…
-
Pro Bono Bio exercises option and obtains exclusive licence from PolyTherics to TheraPEG™ technology for the development of a long-acting Factor VIII as a potential treatment for haemophilia A
London/Moscow, 10th September 2012 – Pro Bono Bio Group plc (“PBB”), the international healthcare group, and PolyTherics Limited (“PolyTherics”), a provider of solutions for the development of…
-
Novacta Biosystems Limited completes Phase I study of NVB302 against C. difficile infection in healthy volunteers
Guernsey and London, 6th August 2012 – Celtic Pharma Holdings Advisors LLP (“CPHA”) today announces that Novacta Biosystems Limited (“Novacta”), a UK biotechnology company focused…
-
Pro Bono Bio and PolyTherics progress and expand their relationship for the development of improved blood factors
London, UK, 29 May 2012 – Pro Bono Bio Group plc (“PBB”), the international healthcare group, and PolyTherics Limited (“PolyTherics”), a provider of solutions for the development…
Welcome to Celtic Pharma Holdings Advisors LLP
Celtic Pharma Holdings Advisors is a global private equity fund management group focused on the biotechnology and pharmaceutical industries. Celtic Pharma and its affiliates have been advising healthcare private equity funds since 2004.